Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fulcrum’s genetic levers

Why Foresite led an $80M series B round for gene regulation play Fulcrum.

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round.

Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Ventures, Section 32,

Read the full 391 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE